Chinese Herbal Decoction Based on Syndrome Differentiation as Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer: An Exploratory and Small Prospective Cohort Study

Figure 2

(a) Median PFS, PPS, and OS were 6.9 months (95% CI, 5.0–8.6 months), 7.6 months (95% CI, 5.5–9.7 months), and 14.5 months (95% CI, 10.6–18.6 months). (b) Patients were grouped by CHD during and after chemotherapy for PFS. (c) In the first phase (the time before disease progression), patients were grouped by CHD >3 months and CHD ≤3 months for PFS. (d) Patients were grouped by PFS >6 months and PFS <6 months for PPS. (e) Patients were grouped by the second phase of CHD >7 months and CHD ≤7 months for PFS. (f) Patients were grouped by CHD >7 months and CHD ≤7 months for PPS.

(a)

(b)

(c)

(d)

(e)

(f)